(Q73764682)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

K S Parsey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Pong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

105-111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Interaction of synthetic progestagens with renal mineralocorticoid receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Effect of Progesterone on Renal Sodium Handling in Man: Relation to Aldosterone Excretion and Plasma Renin Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Natural progesterone and antihypertensive action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Anti-androgenic activity of spironolactone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

Oral contraceptives and cycle control: a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle contr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900083-4

10.1016/S0010-7824(00)00083-4

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10802275%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference